Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980,Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen Switzerland AG
Dammstrasse 21
Postfach 1459
CH-6301 train
Tel: +41 41 369 01 00
Amgen (Europe) GmbH
Dammstrasse 23
Postfach 1557
CH-6301 train
Tel: +41 41 369 03 00
In a wide-ranging interview, Henrik Asmussen outlines his priorities for Amgen’s important Swiss affiliate, market access and pricing challenges, the company’s exciting pipeline, and what makes Amgen Switzerland a great…
Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high…
Amgen has forged a solid position as one of the world’s largest independent biotechnology companies. With a market capitalisation of some USD 130 billion and 27 approved medicines, the US-based…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Ahmed Moustafa outlines the incredible development of the healthcare ecosystem in the UAE driven by a rapid ramping up of the country’s health infrastructure and a willingness on the part…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
Founded in 1980 “at the dawn of a biotechnology revolution,” Amgen has held its ground throughout its more than 40-year history with innovative approaches to drug discovery that have led…
David H. Crean, Ph.D., Managing Partner at Cardiff Advisory, provides his insights on the potential impact of the US Federal Trade Commission (FTC)’s antitrust policies on biopharmaceutical mergers and acquisitions.…
Thanks to its world-renowned networks of medical and academic institutions, the long-standing presence of Big Pharma, and a favourable regulatory environment, Belgium has a well-established tradition of excellence in clinical…
Amgen’s Mohammed Nasser casts his eye on some of the key trends affecting healthcare and the life sciences in the Middle East and Africa, including a significant maturity in uptake…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
As the largest pharma market in MEA in terms of volume and second only behind Saudi in value, Egypt is an increasingly important part of pharma multinationals’ MEA operations. Here,…
As Egypt moves towards universal healthcare coverage for its 100 million-plus population, the country has become the fastest growing pharma market in the Middle East and Africa region with a…
See our Cookie Privacy Policy Here
